AI Article Synopsis
- The triglyceride-glucose (TyG) index may serve as a useful predictor for adverse cardiovascular outcomes in patients suffering from coronary heart disease (CHD) and hypertension.
- A study involving 1,467 hospitalized patients found that an increase in the TyG index correlates with a heightened risk of mortality and cardiovascular events during a one-year follow-up period.
- Specifically, patients in the highest tertile of the TyG index faced a 73% greater risk of primary endpoint events compared to those in the lowest tertile, suggesting that monitoring the TyG index could be important in clinical settings.
Article Abstract
Background: The triglyceride-glucose (TyG) index has been proposed as a potential predictor of adverse prognosis of cardiovascular diseases (CVDs). However, its prognostic value in patients with coronary heart disease (CHD) and hypertension remains unclear.
Methods: A total of 1467 hospitalized patients with CHD and hypertension from January 2021 to December 2021 were included in this prospective and observational clinical study. The TyG index was calculated as Ln [fasting triglyceride level (mg/dL) × fasting plasma glucose level (mg/dL)/2]. Patients were divided into tertiles according to TyG index values. The primary endpoint was a compound endpoint, defined as the first occurrence of all-cause mortality or total nonfatal CVDs events within one-year follow up. The secondary endpoint was atherosclerotic CVD (ASCVD) events, including non-fatal stroke/transient ischemic attack (TIA) and recurrent CHD events. We used restricted cubic spline analysis and multivariate adjusted Cox proportional hazard models to investigate the associations of the TyG index with primary endpoint events.
Results: During the one-year follow-up period, 154 (10.5%) primary endpoint events were recorded, including 129 (8.8%) ASCVD events. After adjusting for confounding variables, for per standard deviation (SD) increase in the TyG index, the risk of incident primary endpoint events increased by 28% [hazard ratio (HR) = 1.28, 95% confidence interval (CI) 1.04-1.59]. Compared with subjects in the lowest tertile (T1), the fully adjusted HR for primary endpoint events was 1.43 (95% CI 0.90-2.26) in the middle (T2) and 1.73 (95% CI 1.06-2.82) in highest tertile (T3) (P for trend = 0.018). Similar results were observed in ASCVD events. Restricted cubic spline analysis also showed that the cumulative risk of primary endpoint events increased as TyG index increased.
Conclusions: The elevated TyG index was a potential marker of adverse prognosis in patients with CHD and hypertension.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257289 | PMC |
| http://dx.doi.org/10.1186/s12933-023-01866-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of dapsone in adult primary immune thrombocytopenia.
Blood Adv
January 2025
Hôpital Henri Mondor, Créteil, France.
To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-word study cohort were performed. Participants were adults with primary ITP, transient response to corticosteroids ± intravenous immunoglobulin, and a platelet count ≤ 30x109/L (or ≤ 50x109/L with bleeding). Patients in the RCT were randomized in arm A (prednisone x3weeks+dapsone for 12 months) or arm B (prednisone alone).
View Article and Find Full Text PDFThe prognosis for patients with acute promyelocytic leukemia (APL) has improved dramatically since the introduction of all-trans retinoic acid (ATRA) and intravenous arsenic trioxide (ATO). However, ATO administration requires daily infusions over several months, representing an onerous burden for hospitals and patients. We evaluated the bioavailability of a novel encapsulated oral ATO formulation in APL patients in first complete remission during standard-of-care consolidation.
View Article and Find Full Text PDFThe efficacy and safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, A randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study.
J Asthma
January 2025
Division of Respiratory Medicine and Allergology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
Persistent cough bothers many patients with asthma because it worsens their quality of life; therefore, it must be remedied immediately. The efficacy of triple therapy as a first-line treatment for cough remains unclear. To evaluate the effectiveness and safety of the triple therapy againts persistent cough, the clinical effect of regular treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or placebo in adult patients with asthma was investigated.
View Article and Find Full Text PDFSmall common bile duct - the risk factor for post-ERCP pancreatitis in patients with choledocholithiasis.
Wiad Lek
January 2025
SALISBURY NHS FOUNDATION TRUST, SALISBURY, UNITED KINGDOM.
Objective: Aim: To investigate the risk factors for PEP in patients with choledocholithiasis.
Patients And Methods: Materials and Methods: We have retrospectively analyzed 253 cases with choledocholithiasis that underwent ERCP. The primary endpoint was the occurrence of PEP.
Body mass index, regional adipose deposition, and clinical outcomes in non-ischemic dilated cardiomyopathy: a prospective cohort study.
Eur J Prev Cardiol
January 2025
Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, P. R. China.
Aim: To assess the relationship between body mass index (BMI), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), epicardial adipose tissue (EAT), pericardial adipose tissue (PAT) and clinical outcomes in dilated cardiomyopathy (DCM) patients.
Methods: Non-ischemic DCM patients were prospectively enrolled. Regional adipose tissue, cardiac function, and myocardial tissue characteristics were measured by cardiac magnetic resonance (CMR).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!